Valuation : Solvonis Therapeutics plc

Market Cap 8.51M 11.54M 9.94M 9.32M 16.03M 1.1B 16.08M 111M 43.14M 557M 43.31M 42.37M 1.85B P/E 2026 *
-2.55x
P/E 2027 * -2.5x
Enterprise Value 6.64M 9M 7.75M 7.27M 12.5M 860M 12.54M 86.24M 33.65M 434M 33.78M 33.04M 1.44B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
53.89%
Yield 2026 *
-
Yield 2027 * -
1 week-16.67%
Current month-1.96%
1 month-9.42%
3 months-50.00%
6 months-50.00%
Current year-59.68%
1 week 0.12
Extreme 0.12
0.15
1 month 0.12
Extreme 0.12
0.17
Current year 0.12
Extreme 0.12
0.33
1 year 0.12
Extreme 0.12
0.4
3 years 0.1
Extreme 0.1
2.65
5 years 0.1
Extreme 0.1
22.46
10 years 0.1
Extreme 0.1
22.46
Manager TitleAgeSince
Chief Executive Officer 50 2024-05-01
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer - 2025-06-02
Director TitleAgeSince
Director/Board Member 50 2024-05-01
Chairman 61 2024-03-14
Chairman 71 2024-09-25
Date Insider Type Main position Quantity % Market Cap.
7/10/24 Free

Director

10,500,000 8.4159%
7/10/24 Free

Responsable ventes & marketing

8,694,000 6.9684%
7/10/24 Free

Director

10,500,000 8.4159%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-16.67%-54.55%-94.57% 11.54M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.38%-2.62%+65.42%+88.23% 27.46B
Weighted average by Cap. -1.70%-1.06%+96.27%+129.02%

Financials

2026 *2027 *
Net sales - -
Net income -3.57M -4.84M -4.17M -3.91M -6.73M -463M -6.75M -46.4M -18.1M -234M -18.17M -17.78M -774M -4.01M -5.44M -4.69M -4.39M -7.55M -520M -7.58M -52.12M -20.33M -262M -20.41M -19.97M -870M
Net Debt -1.87M -2.54M -2.19M -2.05M -3.53M -243M -3.54M -24.34M -9.5M -122M -9.53M -9.32M -406M -6.92M -9.38M -8.08M -7.58M -13.03M -897M -13.07M -89.92M -35.08M -453M -35.22M -34.45M -1.5B
Logo Solvonis Therapeutics plc
Solvonis Therapeutics PLC is a clinical-stage biotechnology company developing treatments for addiction and mental health disorders. The Company is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. It is focused on Alcohol Use Disorder (AUD), which affects over 40 million people across the United States, United Kingdom, and EU4 markets, and Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the United States and approximately 20 million across those same regions. AUD is characterized by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence. PTSD is a complex and debilitating mental health condition that develops in some people who have experienced traumatic events, for example violence, an accident, war or a natural disaster.
Employees
6
Date Price Change Volume
26-08-28 GBX 0.1250 0.00% 15,654,585
26-08-27 GBX 0.1250 0.00% 20,710,574
26-08-26 GBX 0.1250 +2.46% 4,212,561
26-08-25 GBX 0.1220 -12.86% 168,877,452
26-08-24 GBX 0.1400 -6.67% 9,467,000
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.001250GBP
Average target price
0.0170GBP
Spread / Average Target
+1,260.00%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SVNS Stock